Evidence map›Paper›PMID 37289463›Full record

ArticleJAMA ophthalmology2023

Accuracy of Artificial Intelligence in Estimating Best-Corrected Visual Acuity From Fundus Photographs in Eyes With Diabetic Macular Edema.

William Paul, Philippe Burlina, Rohita Mocharla, Neil Joshi, Zhuolin Li, Sophie Gu, Onnisa Nanegrungsunk, Kira Lin, Susan B Bressler, Cindy X Cai and 9 more

Open access · greenAbstract read
In one paragraph

Article in JAMA ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Nonadherence to anti-VEGF intravitreal injections in patients with diabetic macular edema : The names of the authors.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

William PaulApplied Physics Laboratory, Johns Hopkins University, Laurel, Maryland.
Philippe BurlinaApplied Physics Laboratory, Johns Hopkins University, Laurel, Maryland.
Rohita MocharlaApplied Physics Laboratory, Johns Hopkins University, Laurel, Maryland.
Neil JoshiApplied Physics Laboratory, Johns Hopkins University, Laurel, Maryland.
Zhuolin LiDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sophie GuDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Onnisa NanegrungsunkDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Kira LinDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Susan B BresslerDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Cindy X CaiDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jun KongDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
T Y Alvin LiuDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Hadi MoiniRegeneron Pharmaceuticals Inc, Tarrytown, New York.
Weiming DuRegeneron Pharmaceuticals Inc, Tarrytown, New York.
Fouad AmerRegeneron Pharmaceuticals Inc, Tarrytown, New York.
Karen ChuRegeneron Pharmaceuticals Inc, Tarrytown, New York.
Robert VittiRegeneron Pharmaceuticals Inc, Tarrytown, New York.
Farshid SepehrbandRegeneron Pharmaceuticals Inc, Tarrytown, New York.
Neil M BresslerDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins University · USRegeneron (United States) · USJohns Hopkins Medicine · USJohns Hopkins University Applied Physics Laboratory · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Best-corrected visual acuity (BCVA) is a measure used to manage diabetic macular edema (DME), sometimes suggesting development of DME or consideration of initiating, repeating, withholding, or resuming treatment with anti-vascular endothelial growth factor. Using artificial intelligence (AI) to estimate BCVA from fundus images could help clinicians manage DME by reducing the personnel needed for refraction, the time presently required for assessing BCVA, or even the number of office visits if imaged remotely. Objective: To evaluate the potential application of AI techniques for estimating BCVA from fundus photographs with and without ancillary information. Design, Setting, and Participants: Deidentified color fundus images taken after dilation were used post hoc to train AI systems to perform regression from image to BCVA and to evaluate resultant estimation errors. Participants were patients enrolled in the VISTA randomized clinical trial through 148 weeks wherein the study eye was treated with aflibercept or laser. The data from study participants included macular images, clinical information, and BCVA scores by trained examiners following protocol refraction and VA measurement on Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Main Outcomes: Primary outcome was regression evaluated by mean absolute error (MAE); the secondary outcome included percentage of predictions within 10 letters, computed over the entire cohort as well as over subsets categorized by baseline BCVA, determined from baseline through the 148-week visit. Results: Analysis included 7185 macular color fundus images of the study and fellow eyes from 459 participants. Overall, the mean (SD) age was 62.2 (9.8) years, and 250 (54.5%) were male. The baseline BCVA score for the study eyes ranged from 73 to 24 letters (approximate Snellen equivalent 20/40 to 20/320). Using ResNet50 architecture, the MAE for the testing set (n = 641 images) was 9.66 (95% CI, 9.05-10.28); 33% of the values (95% CI, 30%-37%) were within 0 to 5 letters and 28% (95% CI, 25%-32%) within 6 to 10 letters. For BCVA of 100 letters or less but more than 80 letters (20/10 to 20/25, n = 161) and 80 letters or less but more than 55 letters (20/32 to 20/80, n = 309), the MAE was 8.84 letters (95% CI, 7.88-9.81) and 7.91 letters (95% CI, 7.28-8.53), respectively. Conclusions and Relevance: This investigation suggests AI can estimate BCVA directly from fundus photographs in patients with DME, without refraction or subjective visual acuity measurements, often within 1 to 2 lines on an ETDRS chart, supporting this AI concept if additional improvements in estimates can be achieved.

Indexed as

Diabetes MellitusDiabetic RetinopathyMacular EdemaAlgorithmsAngiogenesis InhibitorsArtificial IntelligenceFemaleHumansMaleMiddle AgedVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Identifiers

PMID37289463
PMCPMC10251243
OpenAlexW4379768805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.